Evidence map›Paper›PMID 21272667›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2011

Micellar nanomedicine of human neuropeptide Y.

Antonina Kuzmis, Sok Bee Lim, Esha Desai, Eunjung Jeon, Bao-Shiang Lee, Israel Rubinstein, Hayat Onyüksel

Abstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 30 citations in OpenAlex.

  1. BH3-mimetics: recent developments in cancer therapy.Journal of experimental & clinical cancer research : CR · 2021
    Review
  2. Article
  3. Article
  4. Solubilization of therapeutic agents in micellar nanomedicines.Langmuir : the ACS journal of surfaces and colloids · 2013
    Article
  5. Article
  6. VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.Drug delivery and translational research · 2012
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Antonina KuzmisDepartment of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, USA.
Sok Bee Lim
Esha Desai
Eunjung Jeon
Bao-Shiang Lee
Israel Rubinstein
Hayat Onyüksel
University of Illinois Chicago · USJesse Brown VA Medical Center · US

Funding

Phospholipid Nanocarriers Improve Chemotherapy by Targeted Drug DeliveryR01CA121797 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ONYUKSEL, HAYAT · 2007 to 2010
$1.2M
Micellar VIP Nanoparticles for Rheumatoid ArthritisR01AG024026 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RUBINSTEIN, ISRAEL · 2004 to 2007
$1.1M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015482 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BAUMAN, JERRY L · 2000 to 2000
$909k
NCI NIH HHS CA121797NCI NIH HHS CO6RR15482NCI NIH HHS R01 CA121797NCRR NIH HHS C06 RR015482NIA NIH HHS AG024026NIA NIH HHS R01 AG024026
6 · The paper itself

Abstract

Human neuropeptide Y (NPY) is an important biologics that regulates a multitude of physiological functions and could be amenable to therapeutic manipulations in certain disease states. However, rapid (within minutes) enzymatic degradation and inactivation of NPY precludes its development as a drug. Accordingly, we determined whether self-association of NPY with biocompatible and biodegradable sterically stabilized phospholipid micelles (SSM) improves its stability and bioactivity. We found that in saline NPY spontaneously aggregates; however, in the presence of SSM it self-associates with the micelles as monomers. Three NPY molecules self-associate with 1 SSM at saturation. This process stabilizes the peptide in α-helix conformation, abrogates its degradation by dipeptidyl peptidase-4 and potentiates NPY-induced inhibition of cAMP elaboration in SK-N-MC cells. Collectively, these data indicate that self-association of NPY with SSM stabilizes and protects the peptide in active monomeric conformation, thereby amplifying its bioactivity in vitro. We propose further development of NPY in SSM as a novel, long-acting nanomedicine. FROM THE CLINICAL EDITOR: Human neuropeptide Y (NPY) regulates a multitude of physiological functions and could be amenable to therapeutic manipulations, which is currently limited by its short half life. Self-association of NPY with spherically stabilized micelles (SSM) protects and stabilizes the peptide in active monomeric conformation, thereby amplifying its bioactivity in vitro, enabling future therapeutic considerations.

Indexed as

MicellesCyclic AMPDipeptidyl Peptidase 4Drug StabilityHumansNanomedicineNeuropeptide YPhospholipidsCyclic AMPDipeptidyl Peptidase 4MicellesNeuropeptide YPhospholipids

Identifiers

PMID21272667
PMCPMC3100534
OpenAlexW2021470807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.